Menopausal hormone therapy and incidence, mortality, and survival of breast cancer subtypes: a prospective cohort study

Marit Busund; Giske Ursin; Eiliv Lund; Sairah Lai Fa Chen; Charlotta Rylander

doi:10.1186/s13058-024-01897-4

Menopausal hormone therapy and incidence, mortality, and survival of breast cancer subtypes: a prospective cohort study

Breast Cancer Res. 2024 Nov 4;26(1):151. doi: 10.1186/s13058-024-01897-4.

Authors

Marit Busund¹, Giske Ursin^{2

3

4}, Eiliv Lund⁵, Sairah Lai Fa Chen⁵, Charlotta Rylander⁵

Affiliations

¹ Department of Community Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, 9037, Tromsø, Norway. [email protected].
² Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway.
³ Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.
⁴ Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA.
⁵ Department of Community Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, 9037, Tromsø, Norway.

PMID: 39497219
DOI: 10.1186/s13058-024-01897-4

Abstract

Background: Menopausal hormone therapy (MHT) is associated with an increased risk of postmenopausal breast cancer, predominantly the luminal A-like subtype. The impact of MHT on deaths from breast cancer subtypes is less understood. This study aimed to explore associations between MHT use and the incidence, mortality, and survival of intrinsic-like breast cancer subtypes.

Methods: Data from 160,881 participants with self-reported MHT use from the prospective Norwegian Women and Cancer Study were analyzed. Among them, 7,844 incident breast cancer cases, and 721 breast cancer-specific deaths occurred. Cox proportional hazard regression was performed to calculate hazard ratios (HRs) with 95% confidence intervals (CIs) for the association between MHT use and the incidence, mortality, and survival of breast cancer subtypes.

Results: MHT use was associated with increased risk of overall, luminal A-like, and luminal B-like breast cancer, with respective HRs of 1.44 (95% CI 1.36-1.52), 1.41 (95% CI 1.31-1.52), and 1.23 (95% CI 1.09-1.40) among current estrogen-progestin therapy (EPT) users compared with never users. The risk increased by 4%, 4%, and 2% per year of EPT use for overall, luminal A-like, and luminal B-like breast cancers, respectively. MHT use was also associated with increased risk of overall and luminal A-like breast cancer mortality, with HRs 1.61% (95% CI 1.36-1.91) and 2.15% (95% CI 1.51-3.05) increased risk among current EPT users compared with non-users. Among patients with breast cancer, pre-diagnostic MHT use was not associated with worse survival from overall breast cancer but was inversely associated with survival from triple-negative breast cancer (TNBC; HR death 0.41; 95% CI 0.24-0.73 among current users). Results varied significantly according to tumor subtype (p_{heterogeneity} = 0.02).

Conclusions: Our study suggests that MHT use increases the risk of incident and fatal overall and luminal A-like, and incident luminal B-like breast cancer but does not decrease overall survival among patients with breast cancer. Further research is needed to elucidate the mechanisms underlying MHT use and breast cancer lethality, and to explore whether MHT use among patients with TNBC is indeed free from harm.

Keywords: Breast cancer subtypes; Incidence; Menopausal hormone therapy; Mortality; Survival.